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ABSTRACT 
 Urinary tract infections (UTI)s are a national priority. Women who undergo 
surgery for pelvic floor disorders such as pelvic organ prolapse (POP) or urinary 
incontinence (UI) are at increased risk for UTI, as 10-30% will contract a post-
instrumentation UTI (postI-UTI) within six weeks after surgery. Currently, the factors 
that contribute to the high rate of postI-UTI are unknown, and there is currently no 
clinical assessment to identify at-risk patients. However, antimicrobial peptides (AMPs) 
and characteristics of the urinary microbiota have the potential to serve as biomarkers, 
identifying patients at UTI risk and facilitating clinical prevention studies. 
While it was previously thought that the urinary tract was a sterile environment, 
new evidence shows that bacteria inhabit the urinary tract in many people. Given that 
microbial communities (microbiota) in other areas of the body exist in a balance with 
the host defense system, a similar equilibrium likely exists between the microbiota and 
host defenses in the urinary tract. AMPs, one significant component of our innate 
defense system, can limit pathogenic infection by their abilities to interact with and 
disrupt microbial membranes, and to stimulate immune cell recruitment. While it is 
reported that certain AMPs are expressed in the urinary tract, the AMP profile of the 
urinary tract has not been characterized. Inappropriate expression of AMPs in other 
tissues, including altered levels and/or activity, has been associated with several 
 xii 
different disease states. It is therefore possible that POP/UI surgery patients that 
express inappropriate AMP levels or decreased AMP potency have an imbalance 
between their defenses and their resident microbiota, which results in their 
susceptibility to postI-UTI. 
These results begin to reveal the urinary antimicrobial peptide and microbiota 
profiles of three cohorts of patients: (1) POP/UI patients with culture-negative urine 
samples at baseline who DO NOT develop a postI-UTI (2) POP/UI patients with culture-
negative urine at baseline who DO develop a postI-UTI, and (3) POP/UI patients with 
positive clinical cultures at baseline. While levels of two AMPs, psoriasin and human β-
defensin-1, do not significantly differ between the cohorts, preliminary evidence 
suggests that a characteristic microbiota may exist in patients who develop infection. 
Furthermore, AMPs and the microbiota may directly influence one another. Levels of 
psoriasin are lower in patients with detectable E. coli in their urine than in patients with 
other types of infections. In addition to this correlation, the presence of certain genera 
of bacteria positively correlates with levels of psoriasin. This could indicate that some 
members of the microbiota, by affecting levels of AMPs, influence the susceptibility of 
the urinary tract to invading pathogens. By furthering our understanding of urinary 
AMPs and the urinary microbiota, we take an important step toward being able to 
identify POP/UI patients who are at high risk for postI-UTI, and toward developing new 
therapeutic options for preventing infection.
 
 1 
CHAPTER ONE 
INTRODUCTION - LITERATURE REVIEW 
Clinical Impact of Urinary Tract Infections 
Urinary tract infections (UTIs) are an important and costly clinical problem. 
Different reports suggest that thirty to sixty percent of adult women will experience a 
symptomatic UTI during their lifetime [1, 2]. In the US, it is estimated that there are over 
eight million episodes of UTI per year [3], and the annual cost associated with the 
treatment and care of UTIs is thought to exceed $2 billion [4]. Infections of the lower 
urinary tract, where they are termed cystitis, are associated with symptoms of dysuria, 
frequency, urgency, and lower abdominal or suprapubic pain [2]. Infections of the lower 
urinary tract can ascend to the kidneys causing pyelonephritis with symptoms of fever, 
costovertebral tenderness, nausea and vomiting [2]. Pyelonephritis can result in renal 
scarring and renal failure and can progress to systemic infection and even death [1].  
UTIs are considered uncomplicated if they occur in otherwise healthy non-
pregnant women. UTIs are considered complicated when they occur in patients with 
additional morbidity factors that could contribute to the failure of therapy, such as 
structural or functional abnormalities of the urinary tract, history of renal stones, use of 
catheters, infection with antibiotic-resistant organisms or being immunocompromised 
[2, 3]. Using conventional clinical urine culture techniques to identify bacteria, the most 
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common uropathogen is E. coli, which accounts for 80-85% of UTIs in premenopausal 
women. In postmenopausal women and in women with complicated UTIs, other 
uropathogens, such as K. pneumoniae, Staphylococcus saprophyticus, Proteus, 
Pseudomonas, Enterobacter, Serratia and other Gram-negative enteric bacteria, are 
common [2]. Many of these organisms frequently colonize the gastrointestinal tract and 
infection of the urinary tract is thought to be preceded by colonization of the vagina and 
then the periurethral area. The vaginal bacterial community plays a role in susceptibility 
to UTI. For example, hydrogen-peroxide producing strains of lactobacillus that normally 
inhabit the vagina inhibit the colonization of uropathogens and thereby help prevent 
their transmittance from the gastrointestinal tract to the urinary tract [3].  
Risk factors associated with higher rates of UTI include recent sexual intercourse, 
use of spermicide-associated contraceptive methods [5] and possibly a shorter distance 
between the urethra and the anus [1]. In addition, the association of a number of genes 
with susceptibility to recurrent UTI suggests a possible genetic predisposition for risk of 
infection. These genes encode CXCR1 (the alpha subunit of the IL-8 receptor) [6], CXCR2 
(the beta subunit of the IL-8 receptor), TLR2, TLR4 and TGF-β1 (a cytokine with multiple 
downstream effectors) [2]. All of these genes mediate either adaptive or innate immune 
responses. 
Patients undergoing corrective surgery for pelvic organ prolapse (POP) and/or 
urinary incontinence (UI) are at increased risk for UTI. These surgery patients represent 
a significant population; one study estimated that up to 50% of vaginally parous women 
3 
 
lose pelvic floor support, resulting in prolapse, and found that the likelihood of a woman 
undergoing a POP/UI procedure is 11.1% [7]. Reported rates of post-instrumentation 
UTI (postI-UTI) vary depending on the definition used for UTI diagnosis. One study 
reported a postI-UTI rate of 5.9% in UI patients undergoing midurethral sling 
procedures, defining UTI as symptoms of UTI with a urine culture containing  ≥50,000 
cfu/mL of a single bacterial species within one month after surgery [8]. Another report 
found a postI-UTI rate of 9% in POP/UI surgery patients, defining UTI as irritative voiding 
symptoms accompanied by a positive urine culture within six weeks after surgery [9]. 
Finally, the SISTEr trial, which compared Burch colposuspension with autologous fascial 
sling for the treatment of stress incontinence, and defined UTI as culture-proven 
bladder infection or clinical suspicion of bladder infection resulting in treatment, found 
the rate of postI-UTI to be 48% in patients undergoing the sling procedure and 32% in 
the Burch procedure patients within twenty-four months after surgery [10]. Regardless 
of the definition used, postI-UTI rates are still strikingly high. 
 PostI-UTIs remain a problem despite preventive actions, such as the use of 
standard sterile technique during surgery, the administration of prophylactic antibiotics 
at the time of surgery, and several defensive mechanisms employed by the female 
urinary tract to prevent infection. These defensive mechanisms include shedding of 
uroepithelial cells with adherent microorganisms, secretion of mucus from the 
paraurethral glands to trap bacteria, and the intermittent wash-out of the urethra and 
bladder by the flow of urine [11]. Given all of these defensive and preventive 
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mechanisms, it is currently not known why the prevalence of postI-UTI is so high. Some 
patient characteristics have been identified as risk factors, such as elevated 
preoperative postvoid residual volume [8], but no biomarkers have been identified that 
could serve to identify patients at high risk for postI-UTI.  
Although the high rate of postI-UTIs in this population of POP/UI surgery patients 
is a clinical problem, their well-documented clinical characteristics and their known risk 
make them ideal subjects for the study of UTIs. By recruiting POP/UI patients and 
obtaining urine specimens before the time of surgery and thus before infection, we 
have a unique opportunity to identify differences in the baseline status of patients who 
ultimately come down with infection. Identifying who is at risk for infection will be an 
important first step in understanding why these patients are at risk, and eventually 
lead to the advent of better means of preventing infection. 
It is likely that no single characteristic can be used as an identifying risk factor, 
but rather that a number of factors play a role in indicating who is at risk. Urinary tract 
infections are the result of dynamic interplay between host factors like the innate 
immune system, pathogen factors like the expression of adhesins that aid bacteria in 
attachment and invasion [12], and factors pertaining to the environment of the 
genitourinary tract, such as the presence or absence of commensal bacterial species in 
or around the urinary tract. We will need to study each of these factors in the context of 
the others to fully understand the factors that contribute to risk for postI-UTI. 
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Host-Pathogen Interactions in the Urinary Tract 
As described above, urinary tract infections are likely the outcome of dynamic 
interactions between the host immune system, the pathogens, and other members of 
the microbiota. Illustrative of these dynamics are several interactions that have been 
elucidated between known uropathogens and the human urinary tract. One of the first 
putative mechanisms of host defense that a pathogen will encounter in the urinary tract 
is the outward flow of urine, making the ability to adhere to the uroepithelium an 
important virulence factor. Uropathogens express a variety of adhesion molecules, e.g. 
MR/P fimbriae expressed by Proteus mirabilis and Type-1 Pili expressed by 
uropathogenic E. coli (UPEC) [6]. Type-1 pili bind uroplakin, a structural protein 
expressed on the surfaces of uroepithelial cells, via the FimH adhesin located at the tip 
of the pilus [12]. Both of these uropathogens also secrete toxins that contribute to 
disease, express flagella that aid in motility and ascension of infection, and possess iron 
acquisition systems [6].  
The adhesive interaction of UPEC not only allows it to adhere to the mucosa, but 
also results in the stimulation of various host defense responses. Upon binding by FimH, 
superficial uroepithelial cells, which normally have a very slow turnover rate, are 
stimulated to rapidly exfoliate and to be shed in the urine, taking any adherent 
pathogens with them [13]. Additional innate defense factors include the typically low pH 
and osmolarity of urine, which are not conducive for bacterial growth, and lactoferrin in 
urine, which scavenges the iron necessary for bacterial growth. Other soluble defense 
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factors include Tamm-Horsfall protein, low molecular weight sugars and secretory IgA, 
all of which can bind to bacteria and inhibit their ability to adhere to the epithelial 
surface [12, 14]. The FimH interaction with epithelial cell receptors, augmented by TLR4 
detection of LPS, also induces uroepithelial cells to produce IL-6 and IL-8, which 
subsequently activate a number of inflammatory pathways and recruit neutrophils, 
respectively [12].  
UPEC have developed mechanisms to evade these host defenses. Compared to 
non-uropathogenic E. coli, UPEC elicit a less robust inflammatory response by avoiding 
detection by pattern-recognition receptors and inhibiting the NF-κB mediated 
expression of AMPs, pro-inflammatory cytokines and chemokines [15, 16]. The resulting 
delay in neutrophil recruitment allows UPEC to gain an early foothold, invade epithelial 
cells, and actually utilize the relative safety of the interior of those cells as an 
environment to replicate and persist in biofilm-like communities out of which they may 
periodically emerge. Upon emergence from the intracellular environment, a 
phenomenon termed “fluxing,” some of the cells adopt a filamentous morphology that 
allows them to avoid neutrophil phagocytosis and then reattach to the epithelium [17, 
18]. Thus, these intracellular bacterial communities may serve as reservoirs for 
recurrent infection. 
In recent years, our understanding of the interactions between the host and the 
pathogen during urinary tract infection has vastly expanded. However, there is a gap 
between the body of research knowledge and the realm of clinical practice. Clinical 
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interventions for urinary tract infection have essentially not changed for decades. With 
the increasing prevalence of antibiotic-resistant organisms, and in light of the 
knowledge that some bacteria in the urinary tract could escape the action of antibiotics 
by harboring in epithelial cells, there is a great need for the development of new 
therapeutic practices. These advances should take into account all of the knowledge 
amassed in the research community about patients who are most at risk for infection, 
and should aim to develop prevention methods that could specifically target these 
groups. Such advances will likely manipulate different aspects of the interactions 
between the host, the pathogen and the environment of the urinary tract.  
Relevance of the Microbiota 
Communities of microorganisms are being characterized in several body 
systems, including the oral cavity, the vagina and the gastrointestinal tract [19].  The 
Human Microbiome Project aims to discover the diversity of the microbiota associated 
with humans and to determine if there is a common microbiota profile, termed a “core” 
microbiota, that is prolific in the population and indicative of health. There is some 
evidence that such a core microbiota may exist in the oral cavity, whereas in the vagina 
and gastrointestinal tract, much more variation is observed, and there is no obvious 
single microbiota profile associated with a healthy state [19].  
Nevertheless, there is a plentitude of evidence indicating that our microbiota are 
essential for our health. The microbiota in the gastrointestinal tract are particularly well-
studied. Knowledge of this community provides considerable insight into the complex 
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interactions between the host and the resident microbiota and reveals a truly symbiotic 
relationship. Commensal bacteria in the gut can aid in the production and digestion of 
nutrients, allowing hosts to exploit nutrient sources they would otherwise be unable to 
utilize [20]. For example, many fermenting bacteria can utilize a wide range of 
polysaccharides to produce butyrate, a molecule that serves as a major energy source 
for colonic cells [21]. In studies performed with germ-free mice, it has been shown that 
establishing and maintaining a microbial community in the gastrointestinal tract is 
essential for proper immune system development and function [22]; the microbiota 
modulate the activity of dendritic cells [23] and  T-cells [24] and can contribute to 
proper immune balance through the induction of anti-inflammatory effectors [25]. 
Interaction of the microbiota of the GI tract with the host mucosa provides protection 
against intestinal damage by inducing expression of different genes through TLR 
signaling [26]. There is also evidence that the presence of particular microbes in the 
flora may impart some protection against pathogenic bacteria [27] either by 
competitively binding and inhibiting their adherence [28], competing for nutrients [29] 
or by inhibiting the proliferation of the pathogen through the production of 
antimicrobial compounds [19].  
Similarly, in the vagina, Lactobacillus is often the predominating genus, and is 
thought to inhibit the growth of invasive bacteria through the production of hydrogen 
peroxide, by maintaining a low vaginal pH through the production of lactic acid, and by 
competitively filling an ecological niche [30]. However, this equilibrium can be disturbed 
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when Lactobacillus loses its prominence, and is instead replaced by predominantly 
anaerobic bacteria.  Women with this bacterial profile are much more susceptible to a 
number of urogenital diseases, including bacterial vaginosis, yeast infections, sexually 
transmitted infections including HIV [31] and Neisseria gonorrhoeae [32], and urinary 
tract infections [30].  
The example of Lactobacillus in the vagina demonstrates that the microbiota can 
have a profound influence on the host. The opposite also is true: host factors can play 
an integral role in shaping the microbial community [33]. For example, host genetics can 
play a role in microbial diversity. In one study, decreased diversity was reported to 
correlate with a mutation in a gene associated with familial Mediterranean fever [34]. 
Furthermore, gut microbes are controlled by diverse immune effectors, such as the 
adaptive immune effector secretory IgA, and the innate immune effectors antimicrobial 
peptides [35, 36].  
An imbalance in the dynamic equilibrium between the host and microbiota can 
lead to disease. In many cases, it is not clear if the disruption in the bacterial community 
precedes or results from disease and whether the microbiota disruption is the cause. 
However, in some cases, the causative relationship is fairly clear.  Antibiotic use 
profoundly perturbs the intestinal microbiota composition, interfering with many 
important interactions between members of the bacterial community and with the host, 
often resulting in antibiotic-associated diarrhea (AAD) [37]. In many cases, this 
perturbation allows an opportunistic pathogen to gain a foothold and cause disease. The 
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most common example of this is Clostridium difficile, the leading cause of pathogen-
associated AAD [38]. This association between disruption of the microbiota and 
Clostridium difficile infection gives rise to the idea that restoring the intestinal 
microbiota to its pre-antibiotic status could be beneficial in reestablishing healthy 
interactions, a concept supported by the effective treatment of recurrent C. difficile 
infections by inoculating patients’ GI tracts with donor stool specimens [39]. 
Although much is known about the dynamics of the microbiota at several body 
sites like the GI tract, little is known about the microbiota found in the urinary tract. 
Current dogma states that the urinary tract and the urine within are sterile [40]. This 
dogma arose, largely because clinical practice is to identify infecting organisms via 
culture techniques, which do not grow organisms in the absence of infection. However, 
this concept of sterile urine could merely be due to the fact that a vast majority of 
bacteria are not culturable using these standard laboratory techniques [19]. Even 
normally culturable organisms can enter a state in which they are viable, but not 
culturable [41], and bacteria in this state have been documented in the urine [42]. The 
culture method provides incomplete and skewed information about the bacteria in any 
sample. On the other hand, molecular methods, in use for decades as a means of 
identifying bacteria in the environment [19], provide much more depth and thus a much 
more complete picture of the bacterial community in any sample.  
In fact, recent studies offer culture-independent evidence of bacteria in both the 
male [43, 44] and female urinary tracts [45, 46]. DNA sequencing technology allows us 
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to detect and identify bacteria based on the presence of 16S rRNA genes even in 
culture-negative urine. Given the evidence that interactions between members of the 
microbiota and the host play a significant role in health and disease [47], the discovery 
of bacteria in the urinary tracts suggests the likelihood that a similar dynamic 
environment exists there. Supporting this idea is evidence that, in males, certain urinary 
microbiota profiles dominated by fastidious, anaerobic and uncultivated bacteria can be 
associated with the presence of sexually transmitted infections [44]. Interstitial 
cystitis/bladder pain syndrome (IC/BPS) is a urinary tract disorder with unknown 
etiology. Some studies report an association of low-count microorganisms with IC/BPS 
[48], whereas other studies exclude the possibility of an infectious etiology for IC/BPS 
[49]. However, all of these studies utilized culture-techniques. Culture-independent 
methods might bring clarity to the question of whether bacteria are responsible for 
IC/BPS. It is conceivable that urinary tract diseases with previously unknown etiologies 
may be caused by disruptions in the balance between the normal microbiota and the 
host’s defenses.  
Antimicrobial Peptides 
Antimicrobial peptides (AMPs) are small (i.e. ~10-40 amino acids) cationic, 
amphipathic peptides that serve as an integral component of our innate defense 
system. They exhibit broad-range killing activity against Gram-negative and Gram-
positive bacteria, fungi, protozoa, and enveloped viruses [50]. Several AMPs are 
expressed by humans. Some of the best studied are alpha- and beta-defensins, 
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cathelicidin (LL-37), RNase 7, hepcidin, cathelicidin and psoriasin (S100A7). The 
observation that organisms throughout the plant and animal kingdoms produce AMPs 
suggests that they are evolutionarily ancient and serve an essential role in the defense 
of many species from infection. In humans and other mammals, they are expressed by 
epithelial cells on the skin and at other mucosal surfaces, as well as in granules of 
phagocytic cells [51]. Different classes of AMPs can work together synergistically to 
provide additional antimicrobial activity [52]. As such, they constitute one of our first 
lines of defense against infection. AMPs can recognize and destroy invading pathogens 
even before an inflammatory response is mounted and before innate immune cells, 
such as neutrophils, are recruited to the site of infection. Furthermore, they protect 
against invasive pathogens long before the adaptive immune system can mount an 
antigen-specific response [51, 53-55].  
The cationic and amphipathic properties of these molecules are important 
because they allow AMPs to recognize and interact with microbial membranes, cause 
membrane disruption, and thus ultimately kill the target microbe. Positively charged 
AMPs can distinguish microbial membranes from host cell membranes because the 
former generally contain phospholipids with negative head groups in the outer 
membrane leaflet, while the latter contain phospholipids with no net charge [51, 55].  
There are a few proposed models for the mechanism of membrane disruption. 
The Shai-Matsuzaki-Huang models describe two potential mechanisms. In the barrel-
stave mechanism, low numbers of peptide interact with a target membrane via 
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electrostatic interactions and polymerize to form a pore in the membrane, causing the 
cell to lose membrane potential and allowing contents of the cell to leak out. The carpet 
mechanism states that the peptides, when present at high enough concentrations, will 
spread out across the surface of the membrane causing a loss of membrane curvature 
and leading to the formation of transient toroidal pores [56-58]. Supporting these 
concepts is evidence that the  hydrophobic portion of LL-37 inserts into the core of a 
lipid bilayer altering the capacity of the lipids to pack together properly [59]. In any of 
these cases, the integrity of the cellular contents is compromised allowing for rapid lysis 
of the target cell [51, 55, 60]. There is additional evidence that once the membrane is 
permeabilized, peptides can enter the cell and associate with intracellular targets, 
inhibiting cell-wall, nucleic acid or protein synthesis or inhibiting enzymatic activity [60]. 
More recently, it has been reported that AMPs also serve as important signals 
for the immune system, recruiting immune cells to sites of inflammation and helping to 
enhance host immune activity by inducing the expression of pro-inflammatory cytokines 
and chemoattractant molecules [50, 55]. Cathelicidin, in particular, acts as a chemokine 
for neutrophils, monocytes, mast cells and T-cells [61], and can affect transcription of 
cytokines by macrophages and keratinocytes [62]. Additionally, it plays an important 
role in wound healing, as it stimulates re-epithelialization of skin wounds [63] and 
promotes angiogenesis [64]. Human α-defensins can chemoattract T-cells and induce 
the release of IL-8 from epithelial cells [65]. β-defensin-3 (hBD-3) stimulates monocytes 
to produce the important inflammatory response mediators, IL-6, IL-8 and IL-1β [66]. In 
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human oral epithelial cells, β-defensins stimulate the secretion of the lymphocyte 
chemoattractant MIP-3α [66]. Recently, it was shown that  β-defensin-1 (hBD-1) induces 
neutrophils to form neutrophil extracellular traps (NETs), webs of DNA that trap and kill 
pathogens [67]. Thus, AMPs induce a variety of immune processes and play additional 
roles in host defense apart from their directly antibacterial activities. 
Much is also known about the signals that lead to AMP expression. Production of 
AMPs can be constitutive, or production can be induced by various stimuli. For example, 
hBD-1 is constitutively expressed [68-71]. In contrast, cathelicidin, β-defensin-2 (hBD-2) 
and psoriasin are each induced by the activation of host cell receptors that recognize 
danger-associated molecular patterns (DAMPs), including pathogen-associated 
molecular patterns (PAMPs) [61, 68, 70-72]. For example, hBD-2 expression is induced 
by TLR-2 and TLR-4 activation in intestinal epithelial cells [73]. Flagellin-stimulated 
activation of TLR-5 induces the expression of hBD-2 and psoriasin in epidermal 
keratinocytes [72]. Activation of TLRs results in an intracellular signaling cascade, leading 
to the activation and nuclear translocation of NF-κB. This transcription factor up-
regulates transcription of various genes, including many AMPs and proteins involved in 
AMP-dependent responses [50]. Expression of these inducible AMPs also responds to 
cytokine stimulation and other signals. In intestinal epithelial cells, hBD-2 expression is 
induced by IL-1α. In monocytes, both hBD-2 and cathelicidin are induced by IFN-γ [74]. 
In addition, the promoter for the cathelicidin gene contains a vitamin D response 
element (VDRE) and expression of this peptide is strongly induced by the active form of 
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vitamin D, 1,25-dihydroxyvitamin D3 [75, 76]. Vitamin D-dependent signaling also serves 
as a pathway through which cathelicidin and TLR-2 expression can be upregulated in 
response to injury [77]. Thus, AMPS can be induced by invading pathogens, or by other 
signs of stress, such as inflammation or injury.  
AMPs affect the composition of the resident microbiota, as discussed above, but 
microbes have developed mechanisms for influencing the function or expression of host 
AMPs for their own benefit. One example of a resistance mechanism against AMPs is 
found in Proteus mirabilis, a major uropathogen as previously discussed. This organism 
secretes a metalloprotease, ZapA, with a wide range of targets including AMPs. 
Secretion of ZapA allows P. mirabilis to degrade and thus escape several immune 
elements [78]. On the other hand, the commensal organism Staphylococcus epidermidis 
actually induces the expression of AMPs, including hBD-2 and 3, in keratinocytes on the 
skin via a TLR-2-dependent mechanism. This interaction is beneficial for both the host 
and microbe, because the AMPs kill pathogens on the skin, protecting the host from 
infection, and allowing S. epidermidis to proliferate with fewer competitors for 
resources [79]. 
Nearly all AMPs are synthesized as pro-proteins and undergo a series of 
proteolytic processing steps before reaching their bioactive form. Cathelicidin’s 
proform, for example, consists of two domains, the C-terminal domain which, when the 
peptide is cleaved, goes on to become the mature antimicrobial peptide, and the N-
terminal “cathelin-like” domain. Until recently, it was not known that this cathelin-like 
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domain actually exerts effects of its own; it exhibits antimicrobial activity against E. coli 
and methicillin-resistant S. aureus, and additionally displays protease inhibitory activity, 
possibly serving to mitigate tissue damage during inflammation [80]. The proteases 
responsible for cleaving cathelicidin into its mature form are the serine proteases 
kallikreins 5 and 7. These enzymes are also responsible for further processing mature 
cathelicidin into shorter peptides with various antimicrobial and immune signaling 
activities [81]. The expression of these kallikkreins in keratinocytes is upregulated by 
calcium, vitamin D3, and by retinoic acid [82]. Alpha-defensins are detectable as a 7kD 
prodefensin in granulocytic cells and macrophages before they are processed to their 
mature 3.5kD form, although the enzymes responsible for this processing are not known 
[71]. 
There is much still to learn about the role of antimicrobial peptides in the urinary 
tract. Their importance in this system is shown by knock-out animal models. Both 
cathelicidin-deficient (Camp-/-) mice and β-defensin-1 deficient (Defb1-/-J) mice are more 
susceptible to UTI than their wild-type counterparts. In humans, hBD-1 is constitutively 
expressed by epithelial cells in the kidney [69], while hBD-2 is induced in these cells by 
infections [83]. Other AMPs that have been identified in the urinary tract include α-
defensins derived from neutrophils, and hepcidin which serves dual roles. It is directly 
antimicrobial, and it also regulates iron availability, reducing the amount available for 
invading microbes [83]. However, the specific roles these peptides play in disease and 
infection of the urinary tract has not been entirely elucidated.  
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Concluding Remarks 
 Given all that we know about the dynamic interactions between the host, the 
commensal members of the microbial flora and the pathogens in various body systems, I 
hypothesize that careful analysis of interactions between these diverse players in the 
urinary tract will yield fruitful information about disease and infection. Analyzing urinary 
AMPs, a factor of host defense, and the urinary microbiota in our population of POP/UI 
surgery patients may reveal that certain characteristics in these profiles are indicative of 
risk for postI-UTI. Identifying who is at risk will be an important step toward being able 
to prevent these infections through improved therapeutic intervention. 
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CHAPTER TWO 
 
MATERIALS AND METHODS  
 
Sample Collection and Processing 
We collected transurethral catheterization (TUC) urine samples from POP/UI 
surgery patients at the time of surgery under an IRB approved protocol. Samples were 
held on ice no longer than 4 h before distribution in 3 parts. One fraction was sent to 
the Loyola University Medical Center clinical microbiology laboratory, which determined 
the culture status. One fraction was processed for DNA sequencing by the addition of a 
DNA stabilizing agent. This fraction was then frozen at -80°C until it was shipped to the 
Nelson laboratory at Indiana University-Bloomington, where it was sequenced. A third 
fraction was centrifuged at 13,300 rpm for 20 minutes and the supernatant was filtered 
through a .22um filter to remove particulate matter and cell debris. To solubilize 
peptides in the urine and to inhibit any proteases that may be present, 10% 
trifluoroacetic acid (TFA) was added to each sample to acidify it by reducing the pH to 
approximately three, which yields a final 0.1-0.5% TFA concentration. After the initial 
processing steps, the samples were aliquoted and stored at -80°C until further analysis 
steps. 
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Enzyme-Linked Immunosorbent Assays (ELISA) 
  To measure the concentration of each AMP, I used ELISA kits for human β-
defensin-1 (PeproTech, Cat # 900-K202) and psoriasin (Circulex, Cat # CY-8073) and 
followed the manufacturers’ instructions.  
For the hBD-1 kit, a 96-well plate was incubated with a capture antibody 
overnight and then blocked with 1% BSA for one hour. Samples and standards were 
incubated for two hours and then concentrations of the target peptide were measured 
with a biotinylated detection antibody incubated for two hours, which was itself 
detected with an avidin-HRP conjugate incubated for 30 minutes, and its substrate 2,2'-
azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (green) incubated for approximately 
45 minutes. Absorbances were monitored at five minute intervals with a plate reader at 
405 nm with wavelength correction set at 650 nm until the absorbance for the highest 
standard at 405 nm reached an OD of 1.2.  
For the psoriasin kit, samples and standards were incubated for one hour in a 96-
well plate that had been pre-coated with capture antibody. An HRP-conjugated 
detection antibody was added and incubated for one hour. The substrate was then 
added and the plate was allowed to develop for 10-20 minutes before 1N H2SO4 was 
added to stop the reaction. Absorbance was measured with a plate reader at 450nm 
with wavelength correction set at 540 nm.  
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Values were normalized to the total protein in each sample as measured by a 
Bradford protein assay (Bio-rad, Cat # 500-0006). Dye-reagent was added to the samples 
at a 1:5 ratio and mixed well. Absorbance was measure with a plate reader at 595 nm. 
High Pressure Liquid Chromatography (HPLC) 
Using a Shimadzu HPLC machine, samples were injected onto a C18 column 
(Thermo Scienctific, Cat # 25008-254630) in 90% water, 10% acetonitrile (ACN) mobile 
phase buffer. Over the course of 50 minutes, the concentration of ACN was increased to 
90%. As the concentration increased, increasingly hydrophobic peptides eluted off the 
column. A UV detector at 214 nm measured the peptide bonds, and a UV detector at 
280 nm measured aromatic side chains of amino acids. Fractions of eluate were 
collected at one-minute intervals between 10% and 55% ACN. To ensure each fraction 
contained enough peptide for further analysis, three 1.5 mL aliquots were run 
separately, and the fractions from each run were combined. 
Radial Diffusion Assay (RDA) 
Corresponding fractions from each sample were lyophilized to remove residual 
acetonitrile, reconstituted in sterile water, and vortexed for one hour at 4°C to fully 
dissolve the peptides. The peptide concentration of each fraction was measured by a 
spectrophotometer at 214 nm. Then, more sterile water was added, such that 
corresponding fractions from each sample contained the same peptide concentration. 
For the agar plate, 100 µL of a 108 CFU/mL culture of ΔmprF S. aureus were added per 
25 mL of 0.75% Top agar, and 10 mLs of agar were poured in a plate and allowed to 
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solidify. Wells were made in the agar with vacuum suction through a sterile Pasteur 
pipette. One microliter of each HPLC collected fraction was added to individual wells. 
Positive controls were 100 µM synthetic catestatin and 64 µM synthetic cathelicidin, 
and water was used as a negative control. The plates were incubated overnight at 37°C. 
The area of each zone of inhibition was measured using ImageJ software. 
Protease Assay 
To assess protease activity, an Enzchek protease assay (Invitrogen, Cat # E6638) 
was used, following manufacturer’s instructions. Briefly, samples were incubated with 
BODIPY-FL, a macromolecule containing multiple fluorescent markers that are quenched 
when the molecule is intact. Upon proteolytic cleavage, a green fluorescent signal was 
released. Fluorescence was measured with a microplate reader with excitation and 
emission filters of 485 nm and 530 nm, respectively. 
16S Sequencing and Bioinformatics 
Bacterial DNA sequencing and bioinformatics to determine the identity of 
microbes present in urine samples were performed by our collaborators Dave Nelson 
and Qunfeng Dong, respectively, as described [45]. Briefly, the V1-V3 regions of the 
bacterial 16S rRNA gene were PCR-amplified, bar-coded and sequenced via 
pyrosequencing using the Roche 454 Titanium platform. The resulting sequences were 
analyzed using a BLAST search to identify and discard any sequences with too great a 
homology to human genes, and the remaining sequences were assigned taxonomic 
classifications using RDP Classifier v.2.2. 
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Statistical Analyses 
To facilitate integrated analyses of several different types of data, I have 
constructed a database that includes clinical information about each patient, the 
patients’ responses to a questionnaire that describes the severity of their symptoms, 
the levels of AMPs in their urine and data about their microbiomes, including culture 
status and sequencing data. With the help and direction of Qunfeng Dong, our 
bioinformatician collaborator, we clustered patients based on similarities of their 
microbiota using a Spearman’s rank correlation coefficient as a distance measure. A 
series of univariate and multivariate linear regressions were performed to identify 
correlations between levels of AMPs and the abundance of certain microbes.
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CHAPTER THREE 
EXPERIMENTAL RESULTS 
Urinary Antimicrobial Peptide Levels 
A subset of POP/UI surgery patients will contract a postI-UTI within six weeks of 
surgery. Currently, before surgery, there is no way to identify patients who are at risk 
for a postI-UTI. Because AMPs are antimicrobial agents, we hypothesize that high or low 
levels of one or more urinary AMPs may indicate risk for development of a postI-UTI. 
We therefore compared the AMP levels in the following three cohorts:  
1) Baseline-positive, i.e. patients with culture-positive urine on the day of surgery 
(n = 13) 
2) Baseline-negative, i.e. patients with culture-negative urine on the day of surgery 
who DO NOT develop postI-UTI (n = 122) 
3) PostI-UTI, i.e. patients with culture-negative urine on the day of surgery who DO 
develop a postI-UTI (n = 8) 
Before we could perform this comparison, however, we had to normalize the 
urinary AMP concentrations to account for dilution of the urine due to differences in 
patient solid and liquid consumption. One valid approach is to normalize urinary AMP 
levels to the total protein content of the urine. Through trial and error, we discovered 
that some components in the urine (e.g., creatinine, uric acid or various amino acids) 
24 
 
might interfere with the mechanisms of some of the more commonly used protein 
assays and  thus lead to false positive results. For example, agents with reducing 
potential, chelating agents, and strong acids or bases are known to interfere with BCA 
assays and Lowry assays, because their method of protein detection involves the 
chelation of a metal ion.  
To identify the protein detection method most appropriate for urine, we 
measured six samples with three different assays: a Bradford assay, a modified Lowry 
assay, and a BCA assay. The values from each assay drastically differed even when using 
the same BSA standard concentrations for each assay (Figure 1). Because no two assays 
produced similar results, we were unsure which method yielded the most accurate 
values. We therefore submitted the samples to the clinical core lab at Loyola. They 
measured the protein content of each sample on the Beckman Coulter Synchron DxC800 
system, which uses pyrogallol red and molybdate to form a purple color complex with 
protein that is detectable by measuring absorbance at 600 nm. For each sample tested, 
the results were reported as <60ug/mL, which is their lower limit of detection (data not 
shown). These results agreed most closely with the results obtained with the Bradford 
assay, which by far gave the lowest values. Thus, we concluded that the Bradford assay 
was the most accurate method to measure urinary protein and for the remainder of this 
study, we used the Bradford assay to normalize all of the AMP concentrations. 
To measure the concentrations of the known urinary AMPs, hBD-1 and psoriasin, 
I performed ELISAs. The hBD-1 concentrations varied considerably within each cohort  
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Figure 1. Protein assay comparison with same samples reveals 
discrepancies between assays. (A) The same urine samples tested 
with three protein assays: a Bradford assay, a modified Lowry assay 
and a BCA assay. (B) Results from the Bradford assay alone. 
A 
B 
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and no significant differences were detected (Figure 2a). Between cohorts, the average 
levels of hBD-1 and the distributions of those levels were very similar, with a vast 
majority of the samples exhibiting minimal levels and fewer samples exhibiting greater 
levels of hBD-1. While the concentrations of psoriasin were much lower than those of 
hBD-1 (Figure 2b), the levels of psoriasin generally followed a similar pattern, with the 
majority of the samples exhibiting very low levels and a small proportion displaying 
higher levels. In contrast to those of hBD-1, however, psoriasin levels tended to be 
higher in baseline-positive urine than in the baseline-negative urine, although the 
differences were not significant. Moreover, baseline-positive psoriasin levels 
demonstrated a bimodal distribution. A larger subset of patients in the culture-positive 
cohort expressed relatively high levels of psoriasin, whereas the rest expressed minimal 
levels. Urinary psoriasin was minimal in all patients who were culture-negative at 
baseline, but later contracted a postI-UTI.  
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Figure 2. Urinary antimicrobial peptides, human β-defensin-1 and psoriasin, 
exhibit great variability. Concentrations of hBD-1 (A) and psoriasin (B) in urine 
samples from patients in three cohorts as measured by ELISA and normalized to 
total protein levels. Data points represent mean values of two independent 
ELISAs performed with each sample. 
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Urinary Antimicrobial Peptide Activity 
HBD-1 and psoriasin are just two of the many AMPs that could be present in 
urine. Furthermore, the amount of AMPs present in the urine does not necessarily 
relate directly to their activity. Mutations in the genes that encode AMPs or the genes 
that encode the proteins responsible for correctly processing AMPs can cause different 
individuals to express AMPs with different functional capacities or, in other words, 
different antimicrobial activities. By comparing the functional capacities of AMPs in 
urine samples obtained from patients from all three patient cohorts, we may reveal that 
higher or lower levels of antimicrobial activity are indicative of risk for postI-UTI. To 
assess the antimicrobial activity of AMPs in each urine sample, we fractionated the 
peptides within a sample by HPLC and then performed a solid-phase bacterial-growth-
inhibition assay, the radial diffusion assay.  
To determine when we could expect AMPs to elute off the C18 column during 
HPLC, we ran through the column three solutions of known AMPs. As expected, because 
of their amphipathic nature, the three AMPs, psoriasin, hBD-1 and cathelicidin, eluted 
off the column at an intermediate concentration of acetonitrile in the mobile phase 
buffer, between 40% and 55% acetonitrile (Figure 3a-c). Amphipathic peptides from a 
urine sample eluted between 10% and 55% acetonitrile; therefore, to separate the 
peptides contained in one sample, fractions were collected at one minute intervals 
between these concentrations, which corresponds to minutes 10-35 during one 
fractionation run (Figure 3d).  
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Figure 3. Antimicrobial peptides and urinary peptides elute at various acetonitrile 
concentrations during HPLC. (A-C) Three known AMPs elute between 40% and 55% 
concentration of acetonitrile in water. (D) Urinary AMPs elute between 10% and 
55% concentration of acetonitrile in water. Shaded bars indicate one-minute 
intervals in which fractions of eluate are collected. 
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I compared the tracings between samples from each of the three cohorts. 
Although not universally the case, the HPLC tracings of baseline-positive urine samples 
tended to show larger and more frequent peaks than baseline-negative urine (Figure 4), 
indicating that, in general, culture-positive samples contain a greater variety and higher 
concentrations of peptides and proteins.  
The next step in determining the functional capacity (i.e., antimicrobial activity) 
of urinary AMPs was to subject each HPLC fraction to a radial diffusion assay. This assay, 
which measures antimicrobial activity through bacterial growth inhibition, was 
performed with fractions of a subset of urine samples from each cohort. Antimicrobial 
activity was tested against a ΔmprF Staphylococcus aureus strain. Multiple peptide 
resistance factor (mprF) is a bacterial membrane protein that regulates membrane 
charge by synthesizing and transferring positively charged lysyl-phosphatidylglycerol to 
the outer leaflet of the cell membrane.  Strains with mprF mutations have more 
negatively charged membranes making them more susceptible to cationic AMPs [84]. 
We use this strain, because its susceptiblity to AMPs makes it easier to observe 
differences in antimicrobial activity.  
Urinary peptide fractions from baseline-positive samples tended to exhibit 
greater frequency and magnitude of antimicrobial activity against ΔmprF S. aureus than 
peptide fractions from baseline-negative urine (Figure 5); however, in all three cohorts 
there were samples that did not exhibit antimicrobial activity against this strain in any 
fractions. In this regard, there are no obvious differences between the cohort of 
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baseline-negative patients who develop a postI-UTI (postI-UTI positive) and the cohort 
of baseline-negative patients who do not. Of the samples that exhibited antimicrobial 
activity, some trends are apparent. For example, certain fractions more frequently 
exhibited antimicrobial activity (e.g., fractions 14-16, 24 and 33-34). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
 
 
Figure 4. Baseline-positive urine tends to contain a greater variety and higher 
concentrations of protein and peptides than baseline-negative urine. (A) HPLC 
tracings of two  baseline-positive urine samples. (B) HPLC tracings of two baseline-
negative samples, one from a patient who contracted a postI-UTI, and one from a 
patient who did not. Tracings are representative of their corresponding cohort, 
although not all samples in one cohort always followed the trend. 
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AMPs undergo various stages of proteolytic processing. They are synthesized as 
pro-proteins, which are then cleaved into their bioactive form. Further cleavage 
degrades them. Because proteases are responsible for the processing of AMPs to their 
mature form, antimicrobial activity is integrally associated with protease activity. 
Measuring total protease activity in a sample may reveal that altered protease activity is 
associated with higher or lower antimicrobial activity, giving insight into a possible 
mechanism for that altered antimicrobial activity. To measure total protease activity, an 
Enzchek protease assay was performed on a few samples. In this preliminary study, 
protease activity trended toward higher levels in baseline-positive urine than in 
baseline-negative urine (Figure 6). Due to limited sample numbers and volumes, further 
analyses with this assay were not performed. 
Figure 5. Baseline-positive urinary peptide fractions exhibit greater 
antimicrobial activity. Each column shows corresponding fractions from the 
samples listed along the left. Also noted on the left is the identity of the cultured 
bacteria either in the sample (baseline-positive) or the bacteria cultured from 
the patient within six weeks after surgery (postI-UTI). Values show the area of 
the zone of inhibited growth in square millimeters around fractions that were 
normalized to corresponding fractions from other samples so that all contained 
the same peptide concentration. Darker blue indicates a larger zone of inhibition 
around that fraction. 
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Figure 6. Urinary protease activity trends toward higher levels in 
baseline-positive urine than in baseline-negative urine. Preliminary 
results of protease activity as measured by fluorescence in baseline-
positive and baseline-negative urine (baseline-negative, n = 4; 
baseline-positive n = 6; Bars represent mean  ± SEM; Analyzed by 
Student’s t-test, p = 0.0525) 
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Urinary Microbiota 
 AMPs, an arm of host innate immunity, are known to influence the microbiota of 
various body sites. This may also be true of the urinary tract. Once could easily imagine 
that disruption of the commensal members of the resident urinary bacterial community 
might lead to pathological disease.  To assess the likelihood of this scenario, we first 
must characterize the urinary microbiota, attempting to identify “abnormal” or high-risk 
microbiota profiles. Microbiome analysis was performed in collaboration with Dave 
Nelson, whose research group performed the amplification and sequencing of bacterial 
DNA, and Qunfeng Dong, whose group provided the bioinformatic analysis of the 
resulting data 
 Sixty-three urine samples were analyzed for bacterial 16S DNA sequences. Of 
those 63 samples, 46 (73%) contained high-quality evidence of bacterial DNA, while 17 
(27%) samples contain no conclusive evidence of bacterial DNA. In all of the samples 
with evidence of bacterial DNA, we identified 18 phyla, 100 families, 177 genera, and 
1942 operational taxonomic units (OTUs).  Figure 7 shows a phylogenetic tree of the two 
hundred most frequently sequenced OTUs. This illustration, along with the fact that 
1,942 OTUs were sequenced in total, demonstrates that bacteria are present and 
common in urine, in contrast with the previous dogma of sterile urine. Also of interest is 
the prevalent number of species, or OTUs, that are not associated with any previously 
identified species. This reveals that our previous view of the urinary tract microbial 
community, informed by culture techniques, was not comprehensive. 
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Figure 7. Genetic diversity of urinary microbiota. The two hundred most 
frequent OTUs in all urine samples analyzed. Due to space limitations, a great 
number of less frequent OTUs are not shown. 
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To gain a better picture of the urinary tract microbiota, heat maps were created 
showing the abundance of sequences of the fifteen most abundant bacterial families 
(Figure 8) and the tweny most abundant genera (Figure 9) within each sample. These 
heatmaps revealed that some bacteria tend to be present together. For example, at the 
family level, Corynebacteriaceae and Incertia Sedis XI tend to occur together. At the 
genus level, Corynebacterium and Anaerococcus tended to be present together, and 
Peptoniphilus and Dialister appeared together, also.  
To determine if the microbiota of patients in each cohort were similar, we 
performed a cluster analysis at the family and genus taxonomic levels (Figure 8 and 9). 
Although the number of baseline culture-positive and postI-UTI samples was small (n=1 
and n=2, respectively), it appears that, in terms of their microbiota profiles at the family 
and genus levels, the two postI-UTI samples were more similar to one another than to 
any other samples analyzed. At the family level, the two postI-UTI samples also 
clustered near the one baseline-positive sample. These results indicate that, in a broad 
sense, their microbiota are similar to the baseline-positive sample. One prominent 
family that was prevalent in baseline-negative, postI-UTI negative urine and absent in 
the samples similar to the baseline-positive or postI-UTI positive urine was 
Lactobacilliaceae. Corynebacteriaceae was another family that tended to be present in 
the urine of baseline-negative patients. 
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Figure 8. Microbiota profiles of postI-UTI and baseline-positive samples at the family 
level are similar. Hierarchical heatmap showing abundance of bacteria of the fifteen 
most abundant families. Sequences in these families account for greater than 90% of 
all sequences in all samples analyzed. Green indicates lower abundance; red indicates 
higher abundance. Cluster analysis (shown at top of figure) clusters together samples 
based on similarities in the microbiota profiles using Spearman’s Rank coefficient as a 
measure of distance. 
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Figure 9. Microibiota profiles of postI-UTI positive samples at the genus level 
are similar. Hierarchical heatmap showing abundance of the twenty most 
abundant genera of bacteria. Cluster analysis (shown at top of figure) clusters 
together samples based on similarities in the microbiota profiles using 
Spearman’s Rank coefficient as a measure of distance. 
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Integrated AMP and Microbiota Results 
 Given that urinary tract infections are likely the result of an imbalance amongst 
factors of the host immune system, pathogens and commensal bacteria that shape the 
environment of the urinary tract, studying these different aspects in the context of one 
another will give us a better understanding of who is at risk for infection and potentially 
will lead to new therapeutic options and/or prevention strategies.  
Because psoriasin is known to exert its antimicrobial effects against E. coli, I was 
interested in whether levels of psoriasin correlated with the presence of E. coli. Indeed, 
psoriasin levels were significantly lower in samples with E. coli, detectable either by 
culture or by 16S sequencing, than in samples with other types of culture-verified 
infections (Figure 9). However, in the group of “other infections” there appears to be 
two separate populations, one exhibiting high levels and one exhibiting minimal levels, 
indicating that there may be other factors at play that we do not currently understand.  
Further analysis revealed additional microbiota characteristics that correlate 
with levels of psoriasin. With the help of our collaborator, Qunfeng Dong, a series of 
univariate linear regressions were performed examining possible correlations between 
levels of psoriasin and individual genera of bacteria. By these analyses, we determined 
that numbers of sequences in two genera, Streptococcus and Peptoniphilus, each 
individually correlated with increased levels  of psoriasin (Figure 10). Since two genera 
individually correlated with levels of psoriasin, we next performed a multivariate linear 
regression analysis to determine if multiple genera together correlated with levels of 
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psoriasin. A group of seven genera, Streptococcus, Peptoniphilus, Finegoldia, 
Varibaculum, Peptostreptococcus, Agromonas and Gp3, was identified whose 
abundance positively correlated with amounts of psoriasin. It was determined that 
variation in the abundance of these seven genera accounted for 91% (adjusted R-
squared = 0.9069) of the variance in levels of psoriasin (p < 0.0001).  
  
 
 
 
 
 
 
 
 
Figure 10. Levels of psoriasin are lower in urine with detectable E. coli that in urine 
with other types of infections. Levels of psoriasin are shown for urine samples with   
E. coli detected either by culture or by 16S sequencing and for urine samples with 
another type of culture-detected pathogen. Organisms in the “other infection” 
column include Staphylococcus aureus, Pseudomonas aeruginosa, Corynebacterium 
spp. and Enterococcus spp. (Analyzed by Student’s t-test, p < 0.05) 
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Figure 11. The number of sequences in the genera Streptococcus and Peptoniphilus 
each positively correlate with levels of psoriasin. Levels of psoriasin were compared 
to the number of sequences of either Streptococcus or Peptoniphilus with a 
univariate linear regression analysis. Streptococcus: R = .206, p = 0.03; Peptoniphilus: 
R = 0.182, p = 0.042. 
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CHAPTER FOUR 
DISCUSSION 
Taken together, our data provide some insight into possible interactions 
between the host, its commensal microbiota and pathogenic microbes. Understanding 
these interactions may reveal a profile of risk factors that can identify patients who are 
susceptible to postI-UTI. Once we learn the factors that can identify patients at risk, we 
can begin to develop an assay to assess these measures in patients, and based on those 
measurements, design a course of treatment meant to specifically address the areas in 
which the patient is deficient. This assay would serve as an indispensable tool for 
clinicians.  
Sample Processing 
Because dilution of the urine can vary greatly depending on patient 
consumption, concentrations of peptides of interest must be normalized. This 
normalization permits comparison of values between samples and between cohorts. We 
decided to normalize AMP levels to total protein. However, our data demonstrated that 
not all protein assays are appropriate for use with urine, as certain compounds in urine 
interfere and thus lead to false positive results. For example, some protein assays rely 
on a mechanism that involves the chelation of metal ions by protein; thus, any other 
compounds that cause chelation of metal ions, such as uric acid, can lead to a false 
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positive result. When we compared three commonly used protein assays, a Bradford 
assay, a modified Lowry assay and a BCA assay, we determined that the Bradford 
method was the most appropriate and most accurate, whereas the modified Lowry and 
BCA assays yielded results that were much too high. We henceforth used the Bradford 
assay to measure protein levels. This finding will be important for all future analyses of 
any components of the urine.  
The discrepancies between the results of these three different protein assays 
help to explain some other results that I obtained during my attempt to determine the 
best way to process urine samples for analysis (data not shown). Initially, because I was 
worried that debris or extra substances in the samples would interfere with many of our 
experiments, I dialyzed each sample with membranes with approximately 3.5 kD pore 
sizes. At the time, I was measuring total protein with a BCA assay, and when I measured 
protein levels in dialyzed versus undialyzed urine, it appeared that dialysis caused a 
significant loss of protein (e.g. 5 mg/mL down to 100 µg/mL). Knowing what we know 
now, however, it seems more likely that dialysis actually removed whatever 
components in the samples were resulting in false positive results with the BCA assay. 
At the time, though, we decided dialysis was an inappropriate processing step, because 
it caused too much loss of protein. Now that we know that the BCA assay is an 
inappropriate method to measure urinary protein, it may be worthwhile to revisit the 
use of dialysis as a processing step to remove interfering substances. If this method is 
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used in the future, it may be useful to look into dialysis inserts for 96-well plates that 
allow for dialysis of many samples at one time.  
To separate AMPs from potentially interfering substances, I next experimented 
with the use of centrifuge filters with pore sizes of 3 kD and 30 kD to separate urine 
components into three fractions of <3 kD, 3-30 kD and >30 kD. The AMPs would 
theoretically fall into the 3-30 kD fraction. Using a BCA assay to measure protein, we 
once again found that most of the protein fell into the <3 kD fraction, although we now 
think that we were detecting non-protein components.  
I also utilized these centrifuge filters to assess whether AMPs in the samples 
were fully solubilized. To solubilize the peptides, I began to add trifluoroacetic acid (TFA) 
to samples. I measured hBD-1 concentrations in each fraction of urine samples with and 
without added TFA. I found that without TFA, most hBD-1 could be found in the >30 kD 
fraction. However, with the addition of TFA, most of the hBD-1 would be observed in 
the 3-30 kD fraction (data not shown).This indicated to us that the addition of TFA does 
help solubilize our peptides of interest, allowing for more accurate measurement by 
ELISA. However, not all of the hBD-1 could be found in one fraction, even with the 
addition of acid. To accurately measure AMP concentrations in urine, we decided to 
forgo the use of centrifuge filters, and simply use a 0.2 µm filter to remove cells and 
large debris, and then add TFA to solubilize peptides.  
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Urinary Antimicrobial Peptides 
Analysis by ELISA revealed a wide range of hBD-1 levels in the patients who were 
culture-negative on the day of surgery and did not contract a UTI (baseline-negative), 
the patients who were culture-positive on the day of surgery (baseline-positive), and the 
patients who were culture-negative on the day of surgery but became culture-positive 
after surgery (postI-UTI). Since the distributions were not significantly different, we 
concluded that hBD-1 could not distinguish the three cohorts. 
Likewise, ELISA revealed a wide range of urinary psoriasin in the baseline 
negative and baseline-positive cohorts. The distribution of the baseline-positive cohort 
appeared to be bimodal, with some patients expressing relatively high levels of psoriasin 
and some expressing almost none. In contrast, the level of urinary psoriasin in all postI-
UTI patients was minimal. Since psoriasin expression is generally inducible in the 
presence of infection, it is possible that some patients contracted a UTI (postI-UTI) 
because they were unable to mount a sufficient response. Unfortunately, low psoriasin 
concentration could not be used as a predictor of postI-UTI because it was not restricted 
to the postI-UTI cohort.  
Future studies of urinary AMPs should include more samples in the baseline-
positive cohort and in the postI-UTI cohorts, as this may reveal distinguishing 
characteristics in those patients who ultimately come down with infection.  It also may 
be useful to measure levels of cathelicidin, lactoferrin or hepcidin, three peptides with 
demonstrated antimicrobial activity that have been detected in the urinary tract and 
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that may play a role during infection. I performed one ELISA for cathelicidin in urine 
samples. I was not able to detect any measurable amounts (data not shown); however, 
the ELISA kit had not been validated for use with urine samples. Validating a cathelicidin 
ELISA for use with urine samples, or determining some other way to quantify urinary 
cathelicidin, may be useful for future studies.  
 Running known antimicrobial peptides on a C18 column during HPLC taught us 
where to expect elution of urinary AMPs. Amphipathic peptides in the urine eluted 
between 10% and 55% acetonitrile concentration, so we fractionated peptides by 
collecting fractions at one-minute intervals in that concentration range. This knowledge 
also will be essential for future urine AMP analyses of this kind. We also observed that 
baseline-positive urines generally exhibit larger and more frequent peaks in their HPLC 
tracings, indicating that those samples contain a greater variety and higher 
concentration of peptides and proteins. This is not unexpected, because during infection 
the host up-regulates the expression of a variety of genes [12, 14, 15, 23], so one would 
expect to see a greater number of gene products.  
Included in this host of up-regulated gene products are a variety of AMPs and, as 
expected, the overall antimicrobial activities of baseline-positive urinary peptide 
fractions against ΔmprF S. aureus was higher than activities seen in baseline-negative 
urine. In our small sample size, we did not detect a difference between culture-negative 
urine from patients who DO NOT contract a postI-UTI (i.e., baseline-negative) and 
culture-negative urine from patients who DO contract a postI-UTI (i.e. postI-UTI). 
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Therefore, patients in the postI-UTI cohort could not be identified at baseline based on 
differences in the antimicrobial activities of their urinary AMPs against ΔmprF S. aureus. 
These data exclude the idea that the reason these patients contract infection is due to 
lower antimicrobial activity at the time of surgery; however, these data do not exclude 
the possibility that patients who develop postI-UTIs may be defective in their ability to 
mount an appropriate AMP response in response to an infective insult. 
With this idea in mind, it is worth mentioning that we only tested the 
antimicrobial activities of urinary AMPs against the Gram-positive ΔmprF S. aureus. In 
the future, antimicrobial activities against other relevant bacteria, such as the Gram-
negative E. coli, should also be tested. Such a screen would likely reveal differential 
antimicrobial activity profiles. For example, the urine of baseline-positive patient #817 
cultured E. coli but exhibited widely distributed antimicrobial activity against ΔmprF S. 
aureus. In contrast, the urine of baseline-positive patient #690 also cultured positive for 
E. coli, but exhibited a very limited range of antimicrobial activity against ΔmprF S. 
aureus. Another immediate area of future interest would be to identify the components 
of each fraction by mass spectrometry. This may reveal that certain AMPs are present, 
but not active, which could explain an individual’s susceptibility to infection. Mass 
spectrometry also may reveal previously unknown AMPs in the urine.  
Because proteases play an integral role in processing AMPs from their pro-
peptide forms to their mature forms and in degrading them beyond that, protease 
activity can be intimately associated with antimicrobial activity. I was able to perform 
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one preliminary experiment assessing urinary protease activity and found that protease 
activity trends toward higher levels in baseline-positive urine than in baseline-negative 
urine. This may indicate that, in addition to up-regulating AMPs, the host also activates 
or up-regulates proteases to facilitate more processing of AMPs to their active forms. 
Future studies could expand upon this preliminary experiment to determine if this 
phenomenon holds true with a larger sample size, and perhaps to see if lower protease 
activity might identify patients at risk for postI-UTI before they undergo surgery. To 
determine the role of certain types of proteases, such as the serine proteases that are 
responsible for cleaving cathelicidin, a future experiment could include adding inhibitors 
for these certain classes of proteases, and observing how much of the total protease 
activity disappears. Any future studies on urinary protease activity also may reveal that 
it is useful to normalize these results to total protein to account for dilution of the urine 
due to differences in patient solid and liquid consumption.  
Urinary Microbiota 
In parallel with our initial characterization of the AMP profile of the urinary tract, 
we have begun to characterize the microbiota profile of the urinary tract. The “normal” 
urinary tract is generally considered to be a sterile environment. This dogma is based 
upon culture-based analyses. Using culture-independent DNA-sequencing-based 
techniques, however, we have shown evidence of bacterial DNA in 73% of the urine 
samples analyzed. These results are similar to those previously reported by our research 
team [43-45] and others [46]. 
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A phylogenetic tree of the two hundred most frequent OTUs sequenced provides 
some indication of the microbial diversity that exists in the lower urinary tract. While 
many of the OTUs correspond to well-known bacterial genera, many of the most 
frequent OTUs are unclassified. The fact that so many organisms have not been 
previously characterized highlights the insufficiency of the culture-based methods upon 
which researchers, clinical microbiologists and clinicians have relied to identify bacterial 
residents of the urinary tract [43-46]. This reliance has likely given us a stilted 
understanding of the microbial profiles of the lower urinary tract, especially in relation 
to health and disease.  
Given the existence of urinary bacterial communities, there likely exist countless 
interactions among members of this microbiota as well as between the microbes and 
their hosts. Of these interactions, we know almost nothing. However, given the 
existence of a urinary microbiota, it might be wise to revisit certain clinical situations. 
For example, patients with bacterial vaginosis are at higher risk for urinary tract 
infection [30]. Could it be that the disruption in the vaginal microbiota associated with 
bacterial vaginosis is of secondary importance compared to a disruption in the urinary 
microbiota? This idea is supported by the observation that Lactobacillus was often 
found in the urine of baseline-negative patients who did not contract a postI-UTI, but 
not in the urine of patients that were baseline-positive or contracted a postI-UTI. If this 
hypothesis is valid, then antibiotic treatment for bacterial vaginosis could alter the 
composition of the urinary microbiota, causing the unintended side effect of UTI. 
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To determine whether the urinary microbiota of patients in a given cohort 
resembled the microbiota of other patients in that cohort, we performed a cluster 
analysis and constructed a heat map. At both the family and genus level, patients in the 
baseline-negative cohort clustered into two general groups. At the family level, these 
groups appeared to cluster, in part, on the basis of Lactobacilliaceae. In contrast, at the 
genus level, Lactobacillus was not a defining feature. This difference warrants further 
investigation. 
Unfortunately, the number of samples that produced quality sequences for 
taxonomic classification limited our analysis of the postI-UTI and baseline-positive 
cohorts. In the end, we only had microbiota profiles for two postI-UTI samples and one 
baseline-positive sample. It is perhaps telling that, in spite of the small sample size, that 
the two postI-UTI samples clustered together at both the family and genus levels, 
indicating that their microbiota profiles are more similar to one another than they are to 
any other samples. This encouraging result indicates that there may be a characteristic 
microbiota profile that can identify patients at risk for postI-UTI before they undergo 
surgery. In addition, at the family level these two postI-UTI samples were relatively 
similar to the one baseline-positive sample. This similarity may indicate that the postI-
UTI patients were already on their way to becoming infected: perhaps they were already 
colonized with a pathogen, or their urinary microbiota profiles were more conducive for 
allowing a pathogen to take hold. For example, members of the Lactobacilliaceae family 
were prevalent in many baseline-negative patients who did not develop a postI-UTI, but 
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absent in samples similar to the postI-UTI-positive and culture-positive samples. Perhaps 
the presence of Lactobacilliaceae is indicative of a healthy state. Being able to identify 
patients that are susceptible to infection would be an important step in developing 
clinical interventions to prevent these infections from occurring.  
We also can interpret the microbiota data by asking which bacteria tend to be 
present together. At the family level, for example, Corynebacterium and Incertia Sedis XI 
tend to be present together. At the genus level, Corynebacterium and Anaerococcus 
tend to pair, and Peptoniphilus and Dialister tend to co-exist. At this time, we are unable 
to say if these pairings are clinically relevant, but recognizing trends within the 
microbiota will likely be important in understanding microbiota profiles that are 
indicative of risk for infection. Further statistical analyses should be performed to 
determine if there are any groups of bacteria that exhibit significant correlations, either 
positive or negative, with other groups of bacteria.  
Future studies of microbiota profiles should analyze more samples from the 
postI-UTI and baseline-positive cohorts. In addition, it would be useful to analyze the 
microbiota at a lower taxonomic level, such as the species or strain level. It is entirely 
possible and likely that certain members of each family and genus are more indicative of 
risk for postI-UTI than the entire family or genus. Indeed, some strains of the species E. 
coli are pathogenic (UPEC) whereas other strains are commensal (e.g. K-12). While 16S 
rRNA gene sequencing can distinguish genus and in certain cases species, it does not 
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provide enough depth of information to distinguish between different strains; thus, 
other molecular techniques will be needed if such a level of depth is required.  
Integrated Analyses 
Analysis of AMPs alone did not reveal any characteristics indicative of risk for 
postI-UTI. While analysis of microbiota profiles alone revealed some interesting 
microbiota profiles that could potentially identify patients at risk for postI-UTI, this line 
of investigation requires further exploration. We therefore sought to integrate what we 
know about both factors in the urinary tract. The goal was to reveal relationships that 
might identify patients at-risk for postI-UTI.  
Because psoriasin has been shown to exert its antimicrobial effects against E. 
coli, and because E. coli is such a prevalent uropathogen, appearing several times in our 
culture-positive samples, we wondered whether levels of psoriasin corresponded with 
samples containing E. coli, detectable either by culture techniques or by 16S rRNA gene 
sequencing. Psoriasin levels were significantly lower in samples containing E. coli than in 
other culture-positive samples. This observation is consistent with the notion that 
patients contract an E. coli infection because they are not able to express a sufficient 
antimicrobial response to the initial E. coli insult. Indeed, similar results were found in 
the lung, where psoriasin levels were found to be elevated in the presence of S. aureus, 
but not elevated in the presence of E. coli as detected by culturing bronchoalveolar 
lavage fluid [85].  
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Our collaborator Qunfeng Dong performed univariate linear regression analysis 
on the numbers of sequences of any single genus and the detected levels of psoriasin. In 
doing so, he discovered that the numbers of sequences of two genera, Streptococcus 
and Peptoniphilus, each positively correlated with levels of psoriasin. A multivariate 
linear regression analysis, which is able to account for the combined effect of multiple 
genera on the levels of psorasin, revealed that the numbers of sequences of any of a 
group of seven genera (Streptococcus, Peptoniphilus, Finegoldia, Varibaculum, 
Peptostreptococcus, Agromonas and Gp3) positively correlated with the levels of 
psoriasin. In fact, variance in the number of sequences of these genera could account 
for approximately 91% of the variation in psoriasin concentration. Psoriasin’s positive 
correlation with this defined group of bacteria, and its conspicuous absence in any 
samples containing E. coli could indicate that a microbiota containing a combination of 
bacteria of these seven genera is protective against E. coli infection. It is possible that 
they provide protection by inducing the expression of psoriasin, which is prohibitive for 
the colonization and proliferation of E. coli. Such an interaction would mirror 
interactions at other body sites, where commensal bacteria induce the expression of 
AMPs, consequently protecting the host from infection and removing potential 
competitors from the environment, such as Staphylococcus epidermidis does on the skin 
[79].  
There are any number of future directions in the area of integrated analysis of 
AMPs and the microbiota, not the least of which is performing further statistical 
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analyses on the data we already have. There are likely other correlations that could shed 
light on important interactions; we just need to continue to thoughtfully analyze the 
data to glean from it what we can. There are a few other specific questions to address in 
the future. One is whether certain genera of bacteria correlate with any other AMPs 
besides psoriasin. We could also ask more mechanistic questions about how these 
genera induce psoriasin or any other AMP. Other future experiments could involve using 
either an animal model of UTI or an in vitro system to ask whether the presence of any 
genera associated with higher AMPs is protective against E. coli infection or any other type 
of infection. 
If we can identify a profile of urinary AMPs and/or microbiota that is associated 
with higher risk for postI-UTI, it would then become crucial to develop a tool for 
clinicians to rapidly assess levels of AMPs and certain microbes in a single assay. One 
possibility would be the development of a multiplex assay that utilizes fluorescent 
quantum dots to quantitatively measure levels of different AMPs and levels of bacterial 
DNA from certain different bacteria all in the same assay. If there is more than one 
profile associated with risk, or if there are different profiles associated with risk for 
different types of infection, we could develop a course of treatment that specifically 
aims to correct the area in which that patient is deficient. 
Importantly, it may prove beneficial to shift our focus away from eradication as a 
means of treating infection, and instead treat each body site like the ecologically distinct 
environment that it is, and rather focus on maintaining a healthy ecology. In support of 
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this idea is the successful treatment of pathogen-associated antibiotic-associated 
diarrhea with donor stool samples [39].  This provides an example of how microflora 
disrupted by antibiotics providing an ecological niche for a pathogen to take hold can be 
restored to a healthy state by reintroducing a healthy balance of microorganisms rather 
than by simply trying to eradicate the pathogen. We may find that a good way to treat 
and/or prevent urinary tract infections in POP/UI surgery patients is to optimize the 
urinary microbiota, perhaps by introducing probiotics to establish populations of 
bacteria associated with a healthy state for the host. 
Approaching it from a different angle, we may find that providing exogenous 
AMPs or artificially inducing expression of AMPs is a more effective way of preventing 
infection than prophylactic antibiotics. Another interesting dynamic of AMPs and host 
defense is the report that different people have different copy numbers of hBD-2 
encoded in their genomes. Low hBD-2 copy number has been linked to Crohn’s disease, 
psoriasis and COPD [86], but no similar analysis of hBD-2 copy number has been 
performed in relationship to susceptibility to UTI. This could potentially be an 
interesting area of future research. 
As our understanding grows of the processes and interactions that lead to UTI, 
there is a great need to translate our research knowledge into clinical practice. The 
strikingly high rate of postI-UTI highlights the need for inventive new therapeutics. Any 
areas of future research that seek to translate our understanding into tools that can be 
utilized by clinicians will yield great benefits for patients.
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